Lanraplenib

Phase 2Small molecule

Gilead

Lanraplenib is one of 90 small molecule programs targeting Acute Myeloid Leukemia. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Acute Myeloid LeukemiaActive, not recruiting

Membranous NephropathyActive, not recruiting

Cutaneous Lupus ErythematosusActive, not recruiting

Acute Myeloid LeukemiaPhase 1/Phase 2

Active, not recruiting

Membranous NephropathyPhase 2

Active, not recruiting

Cutaneous Lupus ErythematosusPhase 2

Active, not recruiting

Competition

Competitive Landscape

804 competitors in Acute Myeloid Leukemia

#DrugCompanyPhaseTrials

Novantrone

Pfizer

Phase 3

32 2

Vepesid

AAvyxa

Phase 3

50 3

Cerubidine

HHikma Pharmaceuticals LLC

Phase 3

31 4

Novantrone

EMD Serono

Phase 3

19 5

Alkeran

AApotex Inc.

Phase 3

7 6

Astplayer

AAstex Pharmaceuticals, Inc.

Phase 3

3 7

Retin-a

VValeant Pharmaceuticals

Phase 3

2 8

Lenograstim

Sanofi

Phase 3

1 9

Oblimersen Sodium

NNational Cancer Institute (NCI)

Phase 3

3 10

Sapacitabine

CCyclacel Pharmaceuticals, Inc.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Cutaneous Lupus Erythematosus1 trial

Study to Evaluate Safety and Efficacy of Filgotinib and Lanraplenib in Females With Moderately-to-Severely Active Cutaneous Lupus Erythematosus (CLE)

Completed· Gilead logo

Gilead·Phase 2·NCT03134222·47 enrolled

Impaired Renal Function1 trial

Pharmacokinetics of Lanraplenib in Adults With Impaired Renal Function

Completed· Gilead logo

Gilead·Phase 1·NCT02959138·36 enrolled

Acute Myeloid Leukemia1 trial

A Study to Evaluate Lanraplenib (LANRA) in Combination With Gilteritinib in Participants With FLT3-mutated Relapsed or Refractory Acute Myeloid Leukemia (AML)

Terminated·KKronos Bio·Phase 1/2·NCT05028751·24 enrolled

Safety and Efficacy1 trial

Study to Assess Safety and Efficacy of Filgotinib, Lanraplenib and Tirabrutinib in Adults With Active Sjogren's Syndrome

Completed· Gilead logo

Gilead·Phase 2·NCT03100942·152 enrolled

Membranous Nephropathy1 trial

Study to Evaluate the Safety and Efficacy of Filgotinib and Lanraplenib in Adults With Lupus Membranous Nephropathy (LMN)

Completed· Gilead logo

Gilead·Phase 2·NCT03285711·9 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Lanraplenib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Lanraplenib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Lanraplenib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Gilead company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Gilead

Lanraplenib

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Cutaneous Lupus Erythematosus1 trial

Impaired Renal Function1 trial

Acute Myeloid Leukemia1 trial

Safety and Efficacy1 trial

Membranous Nephropathy1 trial

References

Drug Info

Quick Facts

Related News